Showing results (521-530 of 532) with videos related to
Sort By:
Pageof 54
Lancet (London, England)|March 7, 2021
Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 studyAnthony R Mato, Nirav N Shah, Wojciech Jurczak, et al.Cancer Medicine|September 24, 2020
Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real-world setting. A GIMEMA-ERIC and US studyAntonio Cuneo, Anthony R Mato, Gian Matteo Rigolin, et al.Haematologica|June 9, 2018
Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United StatesAnthony R Mato, Meghan Thompson, John N Allan, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 6, 2017
International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017)A Younes, P Hilden, B Coiffier, et al.Science Translational Medicine|February 4, 2026
Chimeric antigen receptor T cells against the IGHV4-34 B cell receptor specifically eliminate neoplastic and autoimmune B cellsIvan J Cohen, Audrey C Bochi-Layec, Jean Lemoine, et al.Science Immunology|July 19, 2024
CD5 deletion enhances the antitumor activity of adoptive T cell therapiesRuchi P Patel, Guido Ghilardi, Yunlin Zhang, et al.Blood Advances|May 13, 2024
The CNS relapse in T-cell lymphoma index predicts CNS relapse in patients with T- and NK-cell lymphomasRahul S Bhansali, Fredrik Ellin, Thomas Relander, et al.Nature Medicine|March 15, 2022
Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapyMelody Smith, Anqi Dai, Guido Ghilardi, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 22, 2020
Assessment of the Efficacy of Therapies Following Venetoclax Discontinuation in CLL Reveals BTK Inhibition as an Effective StrategyAnthony R Mato, Lindsey E Roeker, Ryan Jacobs, et al.Nature Medicine|January 20, 2025
Long-term safety of lentiviral or gammaretroviral gene-modified T cell therapiesJulie K Jadlowsky, Elizabeth O Hexner, Amy Marshall, et al.Pageof 54